NAPSRx

Sanofi Pasteur, the vaccines division of Sanofi, announced that the U.S. Food and Drug Administration has approved the supplemental biologics license application.

In an advance toward coping with bacteria that shrug off existing antibiotics and sterilization methods, scientists are reporting development of a new family of selective antimicrobial agents that do not rely on traditional antibiotics.

The U.S. Food and Drug Administration is requesting a budget of $4.7 billion to protect and promote the public health as part of the President's fiscal year (FY) 2014 budget.

A new finding could lead to novel treatments to reduce bleeding in trauma and severe infections

Novartis has invited 60 selected students from leading international universities in 21 countries to its headquarters in Switzerland for the International Biotechnology Leadership Camp (BioCamp).

The creation of new blood vessels in the body, called "angiogenesis," is usually discussed in connection with healing wounds and tumors.

A phase 1 clinical trial for the first treatment to reset the immune system of multiple sclerosis (MS) patients showed the therapy was safe and dramatically reduced patients' immune systems' reactivity to myelin by 50 to 75 percent.

A new study at Moffitt Cancer Center could offer hope to people with melanoma, the deadliest form of skin cancer.

Not all placebos are equal, and patients who respond to one placebo don't always respond to others.

A drug approved in Europe to treat osteoporosis has now been shown to stop the growth of breast cancer cells, even in cancers that have become resistant to current targeted therapies, according to a Duke Cancer Institute study.